Characteristics of contacts that developed tuberculosis(TB) disease during follow-up
| Contact | Sex | Age group yrs | Region of birth | Time in NL yrs | Household contact | TST first round mm | TST second round mm | QFT-GIT (IU·mL−1) | T-SPOT.TB® (max spot count minus nil) | Reactive panel (T-SPOT.TB®)# | Time until IGRA testing¶ days | Time to TB+ months | Type of TB | Culture | Case finding§ |
| 1 | M | 16–24 | Asia | 6 | Yes | 15 | ND | Neg. (0.02) | Neg. (0) | None | 34 | 4 | ETB | Pos.## | Passive |
| 2 | M | 16–24 | Sub-Saharan Africa | 5 | Yes | ND | 21 | Pos. (>10) | Pos. (>100) | AB | 137 | 4 | PTB | Neg. | Active |
| 3 | F | 25–34 | Sub-Saharan Africa | 9 | No | 18 | ND | ND | ND | ND | 5 | PTB and ETB | Pos.## | Passive | |
| 4 | F | 35–44 | Sub-Saharan Africa | 3 | Yes | 17 | ND | Neg. (-0.24) | Pos. (11) | B | 19 | 6 | ETB | Pos.## | Active |
| 5 | M | 16–24 | Other Africa | 3 | No | 10 | ND | Neg. (0.04) | Neg. (1) | None | 5 | 8 | PTB | Pos.## | Passive |
| 6 | F | 16–24 | Other Africa | 9 | Yes | 15 | ND | Pos. (>10) | Pos. (47) | AB | 8 | 9 | PTB | Neg. | Active |
| 7 | F | ≥45 | South America | 13 | Yes | 25 | ND | Pos. (0.88) | Pos. (68) | B | 44 | 12 | PTB | Neg. | Passive |
| 8 | M | 35–44 | South America | 15 | Yes | ND | 18 | Pos. (>10) | Pos. (>100) | AB | 92 | 13 | PTB | Pos.## | Active |
| 9 | F | 35–44 | South America | 14 | Yes | NDƒ | NDƒ | Pos. (>10) | Pos. (>100) | AB | 28 | 18 | PTB | Pos.##,¶¶ | Passive |
NL: the Netherlands; TST: tuberculin skin test; QFT-GIT: QuantiFERON TB® Gold In-tube; IGRA: interferon-γ release assay; M: male; F: female; ND: not done; neg.: negative; pos.: positive; ETB: extrapulmonary TB; PTB: pulmonary TB. #: A refers to ESAT-6 and B to CFP-10; ¶: number of days between diagnosis of the index patient and blood collection for IGRA determination; +: number of months between diagnosis of the index patient and diagnosis of TB of the contact; §: passive case finding refers to cases reported spontaneously, while active case finding refers to cases that were found during a screening visit; ƒ: TST known positive, due to previous TB episode; ##: restriction fragment length polymorphism (RFLP) pattern of isolate was identical to that of the index case; ¶¶: isolate was not identical to the RFLP pattern of that of the previous TB episode of this case. QFT-GIT is manufactured by Cellisis, Carnegie, Australia; T-SPOT.TB® is manufactured by Oxford Immunotec, Abingdon, UK.